Roivant Sciences Ltd. ROIV 深 滬
等待開盤 03-26 09:30:00 美东时间
27.36
+0.490
+1.82%
華盛通- 最 高27.965
- 今 開27.25
- 成交量 328.64万股
- 最 低 27.105
- 昨 收 26.87
- 總市值 195.82亿
- 52周最高 30.33
- 市盈率 靜 --
- 換手率 0.46%
- 52周最低 8.73
- 委 比 64.52%
- 總股本 7.16亿
- 歷史最高 30.33
- 量 比 0.43
- 振 幅 3.20%
- 歷史最低 2.52
- 每 手 1
- 風險率 6.13%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Roivant Sciences files Form 8-K/A to add Moderna settlement agreement exhibit
Roivant Sciences files Form 8-K/A to add Moderna settlement agreement exhibit Roivant filed an amended Form 8-K to correct its earlier report by filing the Settlement Agreement as an exhibit. The amendment relates to a March 3, 2026 settlement between Genevant and Arbutus and Moderna that resolves p
03-23 20:44
美股大行评级 | 7家上调，3家下调！CrowdStrike绩后大行评级现分歧；罗斯百货、塔吉特、Viking获多家大行上调目标价
今日重点评级关注：古根海姆：维持Dianthus Therapeutics"买入"评级，目标价从100美元升至200美元；HC Wainwright & Co.：维持Amylyx Pharmaceuticals"买入"评级，目标价从28美元升至34美元
03-05 13:56
莫德纳解决LNP专利纠纷 将支付22.5亿美元和解金
莫德纳（Moderna，MRNA）同意向Roivant Sciences（ROIV）支付高达22.5亿美元，以解决与其COVID-19疫苗相关的脂质纳米颗粒...
03-04 21:35
Roivant Subsidiary Reaches Major Global Patent Settlement
Roivant Sciences ( ($ROIV) ) has provided an update. On March 3, 2026, Roivant’...
03-04 06:14
Roivant Approves $1B Share Buyback Program
The buyback program is inclusive of the $500M authorization that was approved in June 2025
03-04 05:19
Roivant Sciences' Subsidiary, Arbutus Biopharma Sign $2.25B Settlement With Moderna To Resolve All U.S., Global Enforcement Actions; Moderna To Pay $950M Upfront Payment To Genevant, Arbutus
Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio and a subsidiary of Roivant Sciences Ltd. (NASDAQ:ROIV), and Arbutus Biopharma
03-04 05:18
Pfizer-backed Priovant wins FDA priority review for lead asset
Priovant Therapeutics, a company backed by Pfizer (PFE) and Roivant Sciences (ROIV), announced on Tuesday that the U.S. FDA has granted priority review for its marketing application targeted at its le...
03-03 20:24
Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis
The FDA has accepted Priovant Therapeutics' NDA for brepocitinib to treat dermatomyositis (DM) and granted it Priority Review. A PDUFA target action date is set for the third quarter of 2026, with the drug expected to launch in the U.S. by late September 2026. The Priority Review is supported by positive results from the Phase 3 VALOR study, the first successful 52-week placebo-controlled trial in DM, demonstrating significant clinical benefits. ...
03-03 12:00
QVT Financial LP Reports Disposal of Roivant Sciences Ltd. Common Shares
QVT Financial LP Reports Disposal of Roivant Sciences Ltd. Common Shares QVT Financial LP has reported a disposal of common shares of Roivant Sciences Ltd. The transaction involved the sale of 425,000 shares. The full filing can be accessed through the link below. Disclaimer: This news brief was cre
02-14 09:46
美股大行评级 | 安森美半导体获多家大行调目标价；BD医疗、Dynatrace、Monday、Regenxbio遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持内克塔治疗"买入"评级，目标价从135美元升至165美元；BTIG：维持内克塔治疗"买入"评级，目标价从118美元升至151美元
02-11 11:02
